✦ LIBER ✦

Thrombotic microangiopathy complicating pegylated interferon treatment of hepatitis C infection

✍ Scribed by Deena Iskander; Melissa Wickremasinghe; Barbara J. Bain

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 60 KB
Volume: 86
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.22057

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Collapsing glomerulopathy as a complicat

Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection

✍ Sriraj Kanungo; Srinath Tamirisa; Rajalakshmi Gopalakrishnan; Luis Salinas-Madri 📂 Article 📅 2009 🏛 Springer Netherlands 🌐 English ⚖ 196 KB

Effectiveness of hepatitis C treatment w

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

✍ Paul Feuerstadt; Ari L. Bunim; Heriberto Garcia; Jordan J. Karlitz; Hatef Massou 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 2 views

Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%-63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent. The goal of this study was to assess th

Effectiveness of hepatitis C treatment w

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

✍ Ezequiel Ridruejo; Raúl Adrover; Daniel Cocozzella; María Virgina Reggiardo; Nor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 2 views

This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de Promocio´n Cien-tı´fica y Tecnolo´gica).

Prevalence and impact of occult hepatiti

Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin

✍ Marion Levast; Sylvie Larrat; Marie-Ange Thelu; Sandrine Nicod; Agnès Plages; Al 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real‐time PCR techniques are available commercially and ca

Treatment of hepatitis C in hemodialysis

Treatment of hepatitis C in hemodialysis patients using pegylated interferon α-2a in Turkey

✍ Sukran Kose; Alp Gurkan; Fatih Akman; Mehmet Kelesoglu; Ufuk Uner 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 197 KB

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may